ZLABNasdaqPharmaceutical PreparationsFiscal year ends December 31

Zai Lab Ltd

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$24.06+0.87 (+3.75%)

Close on Oct 19, 2026

Market cap: $26.87B
P/E (TTM): –
Dividend yield: –

Zai Lab Ltd income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31
Revenue	460	399	267	215	144	49	13	0.13	–	–	–
Cost of Revenue	191	147	96	74	52	17	3.75	0.04	–	–	–
Gross Profit	270	252	171	141	92	32	9.24	0.09	–	–	–
Research & Development	221	235	266	286	573	223	142	120	39	32	14
Selling, General & Admin	278	299	282	259	219	111	70	22	12	6.38	–
General & Administrative	–	–	–	–	–	–	–	–	12	6.38	2.76
Operating Income	-229	-282	-367	-404	-700	-302	-203	-142	-51	-39	-16
Interest Expense	5.21	2.25	0	0	0	0.18	0.29	0.04	–	–	–
Interest & Investment Income	33	37	40	15	2.19	5.12	8.23	3.26	0.53	0.40	0.01
Income from Equity Investments	–	0	0	-0.22	-1.06	-1.12	-0.75	-0.59	-0.25	–	–
Other Non-Operating Income	3.54	5.30	7.01	3.11	-10	7.42	0.94	0.06	0.53	–	–
Asset Impairment Charges	–	–	–	–	0	0	0	0	0	0	0
Gain (Loss) on Investments	-1.91	-6.11	2.79	-8.95	-15	0	–	–	–	–	–
Gain (Loss) on Sale of Assets	-0.54	-0.45	-0.16	-0.56	-0.03	0.02	-0.02	0.00	-0.01	–	-0.04
Pretax Income	-178	-257	-335	-443	-704	-269	-194	-139	-50	-38	-18
Income Tax Expense	-2.93	0	0	0	0	0	0	0	0	–	–
Net Income	-176	-257	-335	-443	-704	-269	-195	-139	-50	-38	-18
Net Income to Common	-176	-257	-335	-443	-704	-269	-195	-139	-50	-38	-18
EPS (Basic)(per share)	-0.16	-0.26	-0.35	-0.46	-0.76	-0.35	-0.30	-0.26	-0.23	-0.40	-0.21
EPS (Diluted)(per share)	-0.16	-0.26	-0.35	-0.46	-0.76	-0.35	-0.30	-0.26	-0.23	-0.40	-0.21
Shares Outstanding (Basic, Weighted)(shares)	1,095	989	966	958	930	777	644	526	218	94	87
Shares Outstanding (Diluted, Weighted)(shares)	1,095	989	966	958	930	777	644	526	218	94	87
EBITDA	-214	-270	-358	-396	-694	-297	-199	-140	-51	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 56.5%
Operating margin: -58.7%
Net margin: -41.9%
Return on equity, FY2025: -22.6%

Financial strength

Current ratio: 2.13
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 141.8%

Valuation

P/E ratio: –
Price to sales: 59.77
Price to book: 44.27
Dividend yield: –